{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:43:32Z","timestamp":1794246212496,"version":"4.9.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Youth Program of National Natural Science Foundation of China","award":["82301568"],"award-info":[{"award-number":["82301568"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Jinan University Project","award":["40123262"],"award-info":[{"award-number":["40123262"]}]},{"name":"STI 2030 Major Projects","award":["2022ZD0208900"],"award-info":[{"award-number":["2022ZD0208900"]}]},{"name":"STI 2030 Major Projects","award":["2022ZD0211603"],"award-info":[{"award-number":["2022ZD0211603"]}]},{"name":"Guangdong S&T Program","award":["2023B0303040003"],"award-info":[{"award-number":["2023B0303040003"]}]},{"name":"Science and Technology Program of Guangzhou","award":["2023A03J0708"],"award-info":[{"award-number":["2023A03J0708"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02197-8","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:27:06Z","timestamp":1762522026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Patient-reported outcomes of rimegepant for acute and preventive treatment of migraine in China: a prospective, multicenter, real-world study"],"prefix":"10.1186","volume":"26","author":[{"given":"Jinyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongteng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"2197_CR1","doi-asserted-by":"publisher","unstructured":"Global Burden of Disease Study 2016. (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 390, 1211\u20131259. https:\/\/doi.org\/10.1016\/s0140-6736(17)32154-2","DOI":"10.1016\/s0140-6736(17)32154-2"},{"key":"2197_CR2","doi-asserted-by":"publisher","unstructured":"Global Burden of Disease Study 2016. (2018). Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 17, 954\u2013976. https:\/\/doi.org\/10.1016\/s1474-4422(18)30322-3","DOI":"10.1016\/s1474-4422(18)30322-3"},{"key":"2197_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1526-4610.2011.02061.x","volume":"52","author":"S Yu","year":"2012","unstructured":"Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, Fang Y, Cao X, He M, Steiner T (2012) The prevalence and burden of primary headaches in china: a population-based door-to-door survey. Headache 52:582\u2013591. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.02061.x","journal-title":"Headache"},{"key":"2197_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/s0140-6736(19)31606-x","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB (2019) Efficacy, safety, and tolerability of Rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394:737\u2013745. https:\/\/doi.org\/10.1016\/s0140-6736(19)31606-x","journal-title":"Lancet"},{"key":"2197_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ (2019) Rimegepant, an oral calcitonin Gene-Related peptide receptor Antagonist, for migraine. N Engl J Med 381:142\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1811090","journal-title":"N Engl J Med"},{"key":"2197_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ (2021) Oral Rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397:51\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(20)32544-7","journal-title":"Lancet"},{"issue":"10200","key":"2197_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB (2019) Efficacy, safety, and tolerability of Rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394(10200):737\u2013745. https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X","journal-title":"Lancet"},{"issue":"6","key":"2197_CR8","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1474-4422(23)00126-6","volume":"22","author":"S Yu","year":"2023","unstructured":"Yu S, Kim BK, Guo A, Kim MH, Zhang M, Wang Z, Liu J, Moon HS, Tan G, Yang Q, McGrath D, Hanna M, Stock DA, Gao Y, Croop R, Lu Z (2023) Safety and efficacy of Rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 22(6):476\u2013484. https:\/\/doi.org\/10.1016\/S1474-4422(23)00126-6","journal-title":"Lancet Neurol"},{"key":"2197_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021\u20131039. https:\/\/doi.org\/10.1111\/head.14153","journal-title":"Headache"},{"key":"2197_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lant\u00e9ri-Minet M, Braschinsky M, Del Rio MS, Daniel O, \u00d6zge A, Mammadbayli A, Arons M, Skorobogatykh K, Romanenko V, Terwindt GM, Paemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina M (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17:501\u2013514. https:\/\/doi.org\/10.1038\/s41582-021-00509-5","journal-title":"Nat Rev Neurol"},{"key":"2197_CR11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.neurol.2021.07.006","volume":"177","author":"A Ducros","year":"2021","unstructured":"Ducros A, de Gaalon S, Roos C, Donnet A, Giraud P, Gu\u00e9gan-Massardier E, Lant\u00e9ri-Minet M, Lucas C, Mawet J, Moisset X, Valade D, Demarquay G (2021) Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: Pharmacological treatment. Rev Neurol (Paris) 177:734\u2013752. https:\/\/doi.org\/10.1016\/j.neurol.2021.07.006","journal-title":"Rev Neurol (Paris)"},{"key":"2197_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/a:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr., Garber WH, Batenhorst A, Cady R, Dahl\u00f6f CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963\u2013974. https:\/\/doi.org\/10.1023\/a:1026119331193","journal-title":"Qual Life Res"},{"key":"2197_CR13","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/head.13946","volume":"60","author":"CR Houts","year":"2020","unstructured":"Houts CR, Wirth RJ, McGinley JS, Cady R, Lipton RB (2020) Determining thresholds for meaningful change for the headache impact test (HIT-6) total and Item-Specific scores in chronic migraine. Headache 60:2003\u20132013. https:\/\/doi.org\/10.1111\/head.13946","journal-title":"Headache"},{"issue":"1","key":"2197_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0333102413497599","volume":"34","author":"AF Smelt","year":"2014","unstructured":"Smelt AF, Assendelft WJ, Terwee CB, Ferrari MD, Blom JW (2014) What is a clinically relevant change on the HIT-6 questionnaire? An Estimation in a primary-care population of migraine patients. Cephalalgia 34(1):29\u201336. https:\/\/doi.org\/10.1177\/0333102413497599","journal-title":"Cephalalgia"},{"key":"2197_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR (2004) Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a National panel study of chronic disease. Health Qual Life Outcomes 2:12. https:\/\/doi.org\/10.1186\/1477-7525-2-12","journal-title":"Health Qual Life Outcomes"},{"key":"2197_CR16","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K (2017) Estimating an EQ-5D-5L value set for China. Value Health 20:662\u2013669. https:\/\/doi.org\/10.1016\/j.jval.2016.11.016","journal-title":"Value Health"},{"key":"2197_CR17","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"key":"2197_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4:353\u2013365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006","journal-title":"PharmacoEconomics"},{"key":"2197_CR19","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/head.13115","volume":"57","author":"RB Lipton","year":"2017","unstructured":"Lipton RB, Munjal S, Buse DC, Bennett A, Fanning KM, Burstein R, Reed ML (2017) Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American migraine prevalence and prevention study. Headache 57:1026\u20131040. https:\/\/doi.org\/10.1111\/head.13115","journal-title":"Headache"},{"key":"2197_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008615.pub2","author":"CJ Derry","year":"2012","unstructured":"Derry CJ, Derry S, Moore RA (2012) Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012:Cd008615. https:\/\/doi.org\/10.1002\/14651858.CD008615.pub2","journal-title":"Cochrane Database Syst Rev 2012:Cd008615"},{"key":"2197_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/j.1526-4610.2003.03073.x","volume":"43","author":"G G\u00e9raud","year":"2003","unstructured":"G\u00e9raud G, Keywood C, Senard JM (2003) Migraine headache recurrence: relationship to clinical, pharmacological, and Pharmacokinetic properties of triptans. Headache 43:376\u2013388. https:\/\/doi.org\/10.1046\/j.1526-4610.2003.03073.x","journal-title":"Headache"},{"key":"2197_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s10194-024-01873-5","volume":"25","author":"Z Yang","year":"2024","unstructured":"Yang Z, Wang X, Niu M, Wei Q, Zhong H, Li X, Yuan W, Xu W, Zhu S, Yu S, Liu J, Yan J, Kang W, Huang P (2024) First real-world study on the effectiveness and tolerability of Rimegepant for acute migraine therapy in Chinese patients. J Headache Pain 25:160. https:\/\/doi.org\/10.1186\/s10194-024-01873-5","journal-title":"J Headache Pain"},{"key":"2197_CR23","doi-asserted-by":"publisher","first-page":"333102425131801","DOI":"10.1177\/03331024251318016","volume":"45","author":"P Pozo-Rosich","year":"2025","unstructured":"Pozo-Rosich P, van Veelen N, Caronna E, Vaghi G, Torres-Ferrus M, van der Arend BWH, Goadsby PJ, Ashina M, Wang SJ, Diener HC, Tassorelli C, Terwindt GM (2025) Guidelines of the international headache society for Real-World evidence studies in migraine and cluster headache. Cephalalgia 45:3331024251318016. https:\/\/doi.org\/10.1177\/03331024251318016","journal-title":"Cephalalgia"},{"key":"2197_CR24","doi-asserted-by":"publisher","first-page":"e764","DOI":"10.1212\/wnl.0000000000201568","volume":"100","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes JT, Creutz L, Gandhi P, Dodick D (2023) Effect of Atogepant for preventive migraine treatment on Patient-Reported outcomes in the Randomized, Double-blind, phase 3 ADVANCE trial. Neurology 100:e764\u2013e777. https:\/\/doi.org\/10.1212\/wnl.0000000000201568","journal-title":"Neurology"},{"key":"2197_CR25","doi-asserted-by":"publisher","first-page":"333102423119029","DOI":"10.1177\/03331024231190296","volume":"51","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Halker Singh RB, Mechtler L, McVige J, Ma J, Yu SY, Stokes J, Dabruzzo B, Gandhi P, Ashina M (2023) Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily Atogepant for preventive treatment of migraine in a randomized, 52-week trial. Cephalalgia 51:3331024231190296. https:\/\/doi.org\/10.1177\/03331024231190296","journal-title":"Cephalalgia"},{"issue":"10","key":"2197_CR26","doi-asserted-by":"publisher","first-page":"333102425137168","DOI":"10.1177\/03331024251371686","volume":"45","author":"M Zhang","year":"2025","unstructured":"Zhang M, Guo A, Wu J, Wang H, Zhang Y, Dong H, Liu J, Zhang B, Guo H, Yu T, Lu Z, Ma L, Fountaine RJ, Pixton GC, Zhong Q, Han X, Yu S (2025) Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China. Cephalalgia 45(10):3331024251371686. https:\/\/doi.org\/10.1177\/03331024251371686","journal-title":"Cephalalgia"},{"key":"2197_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/s0140-6736(04)15440-8","volume":"363","author":"SD Silberstein","year":"2004","unstructured":"Silberstein SD (2004) Migraine Lancet 363:381\u2013391. https:\/\/doi.org\/10.1016\/s0140-6736(04)15440-8","journal-title":"Migraine Lancet"},{"key":"2197_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40120-023-00562-w","volume":"13","author":"TJ Schwedt","year":"2024","unstructured":"Schwedt TJ, Myers Oakes TM, Martinez JM, Vargas BB, Pandey H, Pearlman EM, Richardson DR, Varnado OJ, Cobas Meyer M, Goadsby PJ (2024) Comparing the efficacy and safety of galcanezumab versus Rimegepant for prevention of episodic migraine: results from a Randomized, controlled clinical trial. Neurol Ther 13:85\u2013105. https:\/\/doi.org\/10.1007\/s40120-023-00562-w","journal-title":"Neurol Ther"},{"key":"2197_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11910-020-01067-x","volume":"20","author":"T Ansari","year":"2020","unstructured":"Ansari T, Lagman-Bartolome AM, Monsour D, Lay C (2020) Management of menstrual migraine. Curr Neurol Neurosci Rep 20:45. https:\/\/doi.org\/10.1007\/s11910-020-01067-x","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2197_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41582-021-00544-2","volume":"17","author":"DN Krause","year":"2021","unstructured":"Krause DN, Warfvinge K, Haanes KA, Edvinsson L (2021) Hormonal influences in migraine - interactions of oestrogen, Oxytocin and CGRP. Nat Rev Neurol 17:621\u2013633. https:\/\/doi.org\/10.1038\/s41582-021-00544-2","journal-title":"Nat Rev Neurol"},{"key":"2197_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5214\/ans.0972.7531.190403","volume":"19","author":"M Aggarwal","year":"2012","unstructured":"Aggarwal M, Puri V, Puri S (2012) Effects of Estrogen on the serotonergic system and calcitonin gene-related peptide in trigeminal ganglia of rats. Ann Neurosci 19:151\u2013157. https:\/\/doi.org\/10.5214\/ans.0972.7531.190403","journal-title":"Ann Neurosci"},{"key":"2197_CR32","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/head.14619","volume":"63","author":"EA MacGregor","year":"2023","unstructured":"MacGregor EA, Hutchinson S, Lai H, Dabruzzo B, Yu SY, Trugman JM, Ailani J (2023) Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis. Headache 63:1135\u20131144. https:\/\/doi.org\/10.1111\/head.14619","journal-title":"Headache"},{"issue":"1","key":"2197_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s10194-025-02028-w","volume":"18","author":"L Pellesi","year":"2025","unstructured":"Pellesi L, Do TP, Ernst MT, Hallas J, Potteg\u00e5rd A (2025) Adoption of Rimegepant in denmark: a register-based study on uptake, prescribing patterns and initiator characteristics. J Headache Pain 18(1):83. https:\/\/doi.org\/10.1186\/s10194-025-02028-w","journal-title":"J Headache Pain"},{"key":"2197_CR34","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2147\/JPR.S456006","volume":"15","author":"T Fullerton","year":"2024","unstructured":"Fullerton T, Pixton G (2024) Long-Term use of Rimegepant 75\u00a0mg for the acute treatment of migraine is associated with a reduction in the utilization of select analgesics and antiemetics. J Pain Res 15:17:1751\u20131760. https:\/\/doi.org\/10.2147\/JPR.S456006","journal-title":"J Pain Res"},{"issue":"11","key":"2197_CR35","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/14737175.2024.2401558","volume":"24","author":"WD Wells-Gatnik","year":"2024","unstructured":"Wells-Gatnik WD, Pellesi L, Martelletti P (2024) Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine. Expert Rev Neurother 24(11):1107\u20131117. https:\/\/doi.org\/10.1080\/14737175.2024.2401558","journal-title":"Expert Rev Neurother"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02197-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02197-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02197-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:27:07Z","timestamp":1762522027000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02197-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2197"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02197-8","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with standards of Good Clinical Practice as defined by the International Conference on Harmonisation. The central institutional review board or ethics committee approved the study at each site, and patients provided written informed consent before any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}